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Nina Van Opdenbosch1,2,6, Anvesh Jallapally7, Ruth Geiss-Friedlander8 , Anne-Marie Lambeir3 , Koen Augustyns7 ,
Pieter Van Der Veken7, Ingrid De Meester3 , Mohamed Lamkanfi1,2,6
Activating germline mutations in the human inflammasome
sensor NLRP1 causes palmoplantar dyskeratosis and suscepti-
bility to Mendelian autoinflammatory diseases. Recent studies
have shown that the cytosolic serine dipeptidyl peptidases DPP8
and DPP9 suppress inflammasome activation upstream of NLRP1
and CARD8 in human keratinocytes and peripheral blood
mononuclear cells. Moreover, pharmacological inhibition of
DPP8/DPP9 protease activity was shown to induce pyroptosis in
murine C57BL/6 macrophages without eliciting other inflamma-
some hallmark responses. Here, we show that DPP8/DPP9 in-
hibition in macrophages that express a Bacillus anthracis lethal
toxin (LeTx)–sensitive Nlrp1b allele triggered significantly ac-
celerated pyroptosis concomitant with caspase-1 maturation,
ASC speck assembly, and secretion of mature IL-1β and IL-18.
Genetic ablation of ASC prevented DPP8/DPP9 inhibition-induced
caspase-1 maturation and partially hampered pyroptosis and
inflammasome-dependent cytokine release, whereas deletion
of caspase-1 or gasdermin D triggered apoptosis in the ab-
sence of IL-1β and IL-18 secretion. In conclusion, blockade of
DPP8/DPP9 protease activity triggers rapid pyroptosis and ca-
nonical inflammasome hallmarks in primary macrophages that
express a LeTx-responsive Nlrp1b allele.
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Introduction
Inflammasomes play critical roles in the host response against
pathogenic invasion and in inflammatory responses elicited by a
diversity of host-derived and environmental stressors (Lamkanfi &
Dixit, 2012, 2014). Canonical inflammasomes are assembled when
the germline-encoded intracellular pattern recognition receptors
nucleotide-binding oligomerization domain, leucine rich repeat
and pyrin domain containing (NLRP)1, NLRP3, NLRC4, absent in
melanoma (AIM2), and Pyrin detect so-called pathogen-associated
molecular patterns and damage-associatedmolecular patterns. These
cytosolic multi-protein platforms promote proximity-induced auto-
activation of the cysteine protease caspase-1, which in turn cleaves the
cytosolic precursor forms of interleukin (IL)-1β and IL-18 into mature
inflammatory cytokines. Furthermore, inflammatory caspase-driven
cleavage of gasdermin D (GSDMD) causes oligomerization and
membrane internalization of the amino-terminal pore-forming
domain, resulting in the hallmark features of pyroptosis including
plasmamembrane perforation, cell lysis, and the extracellular release
of the soluble intracellular content (Kayagaki et al, 2015; Shi et al, 2015;
Aglietti et al, 2016; Ding et al, 2016; Liu et al, 2016; Sborgi et al, 2016).
Whereas canonical inflammasomes drive caspase-1 activation
directly, intracellular Gram-negative lipopolysaccharides activate the
inflammatory caspases -4, -5, and -11 in a signalling cascade referred
to as the non-canonical inflammasome pathway (Kayagaki et al, 2011).
The latter inflammatory caspases elicit pyroptosis autonomously,
while engaging the NLRP3 inflammasome downstream of GSDMD for
caspase-1–mediated secretion of IL-1β and IL-18 (Kayagaki et al, 2011).
Gain-of-function mutations in the inflammasome pattern rec-
ognition receptors NLRP3, Pyrin, and NLRC4 cause systemic auto-
inflammatory diseases that are frequently characterized by periodic
fevers that last 3 to 7 d and recur every 2 to 12 wk, along with skin
rash, abdominal pain, and other symptoms (Van Gorp et al, 2017).
Notably, gain-of-function mutations in NLRP1 cause early onset skin
inflammatory and epithelial dyskeratosis syndromes, whereas re-
curring fever is more variable in patients with NLRP1 mutations
(Grandemange et al, 2016; Zhong et al, 2016). In addition to the
prototypical PYD, NACHT, and Leucine-rich repeat domains found in
other NLRP family members, NLRP1 contains a unique carboxy-
terminus extension that harbours a function-to-find (FIIND) domain
and a CARD. The FIIND domain is an autoproteolytic domain that
is uniquely shared between NLRP1 and CARD8 and undergoes
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posttranslational autocleavage as a prerequisite for ligand-induced
activation (D’Osualdo et al, 2011; Finger et al, 2012; Frew et al, 2012).
Rodents lack a CARD8 homolog, but encode three orthologous
NLRP1 genes: Nlrp1a, Nlrp1b, and Nlrp1c (Boyden & Dietrich, 2006).
Murine Nlrp1c is considered a pseudogene, whereas both Nlrp1a
and Nlrp1b are established inflammasome sensors. An N-ethyl-N-
nitrosourea mutagenesis screen for dominant mutations identified
an activating Nlrp1aQ593P mutation that drove IL-1–dependent
leukopenia in unchallenged mice by promoting excessive inflam-
masome activation and pyroptosis in hematopoietic progenitor
cells (Masters et al, 2012). Bacillus anthracis lethal toxin (LeTx) is a
well-defined biochemical virulence factor that potently triggers
activation of the Nlrp1b inflammasome and pyroptosis in macro-
phages of genetically susceptible inbred mouse and rat strains
(Boyden & Dietrich, 2006; Moayeri et al, 2010). Murine Nlrp1b is
highly polymorphic, encoding five different alleles that drive
macrophage susceptibility to LeTx in various inbred mouse strains
(Boyden & Dietrich, 2006). Allele 1—found in 129S and BALB/c
mice—and allele 5—found in the CAST/EiJ mouse strain—promote
macrophage susceptibility to LeTx intoxication. On the other hand,
allele 2 of A/J and C57BL/6J (B6) mice and alleles 3 and 4 in other
inbred strains do not respond to LeTx and confer resistance to
LeTx-induced pyroptosis in macrophages from these inbred strains
(Boyden & Dietrich, 2006; Moayeri et al, 2010). Although it cannot be
ruled out that the LeTx-unresponsive B6-derived Nlrp1b allele may
have yet undiscovered activities, no studies to date have formally
established that it is capable of eliciting inflammasome activation in
response to endogenous, environmental, microbial, and pharmaco-
logical agents, and inflammasome activation upon LeTx intoxication
has only been formally demonstrated in the presence of allele 1 of
Nlrp1b (Boyden & Dietrich, 2006; Van Opdenbosch et al, 2014).
Recent studies have shown that pharmacological inhibitors of
the S9B family of post-proline dipeptidyl peptidases (DPP)8 and
DPP9 activate NLRP1 and CARD8 to induce pyroptosis in human
keratinocytes, the human monocytic-like cell line THP-1, and in
primary peripheral blood mononuclear cells, respectively (Johnson
et al, 2018; Zhong et al, 2018). A recent report showed that DPP8/
DPP9 inhibition in human keratinocytes elicited the known hall-
mark features of canonical inflammasome activation, including
caspase-1 autocleavage, apoptosis-associated speck-like protein
containing a CARD (ASC) speck formation, and secretion of mature
IL-1β and IL-18 (Zhong et al, 2018). However, it is less clear whether
these inflammasome responses are elicited upon DPP8/DPP9 in-
hibition in human and murine mononuclear cells (Okondo et al,
2017; Johnson et al, 2018; Zhong et al, 2018). The competitive pan-
DPP inhibitor Val-boroPro (VBP) (Coutts et al, 1996) and the more
selective DPP8/DPP9 protease inhibitor 1G244 (Jiaang et al, 2005)
were reported to induce pyroptosis without eliciting ASC speck
assembly, ASC-dependent caspase-1 auto-maturation, or matura-
tion and secretion of IL-1β from murine B6 macrophages, and the
immortalized monocytic cell line RAW 264.7 (Okondo et al, 2017,
2018). However, B6 macrophages lack a LeTx-responsive Nlrp1b
allele (Boyden & Dietrich, 2006; Van Opdenbosch et al, 2014), and
the BALB/c-derived RAW 264.7 cell line lacks expression of
the inflammasome adaptor protein ASC (Pelegrin et al, 2008).
These observations prompted us to evaluate the inflammasome
responses that are elicited by inhibition of DPP8/DPP9 in primary
BMDM of mice that either express or lack LeTx-responsive Nlrp1b
alleles. Our results demonstrate that DPP8/DPP9 inhibition signifi-
cantly sensitizes macrophages that express a LeTx-responsive Nlrp1b
allele to rapid pyroptosis induction concomitant with caspase-1
maturation, ASC speck assembly, and secretion of mature IL-1β and
IL-18. Moreover, we show that genetic ablation of ASC in macro-
phages with a LeTx-responsive Nlrp1b allele prevented DPP8/DPP9
inhibition–induced caspase-1 maturation and partially hampered
pyroptosis and inflammasome-dependent cytokine release, whereas
deletion of caspase-1 or GSDMD triggered apoptosis in the absence of
IL-1β and IL-18 secretion. In conclusion, our results demonstrate that
DPP8/DPP9 protease activity suppresses caspase-1 maturation, ASC
speck formation, cytokine secretion, and rapid pyroptosis in macro-
phages that express a LeTx-responsive Nlrp1b allele.
Results
Hemizygous expression of a LeTx-responsive Nlrp1b allele in
C57BL/6J macrophages accelerates DPP8/DPP9
inhibition–induced pyroptosis
Wild-type B6 mice lack a LeTx-responsive Nlrp1b allele, rendering
their BMDMs insensitive to B. anthracis LeTx-induced pyroptosis,
but hemizygous expression of a LeTx-responsive Nlrp1b allele from
a 129S1-derived BAC (B6Nlrp1b+ mice) fully rescues LeTx-induced
pyroptosis (Boyden & Dietrich, 2006; de Vasconcelos et al, 2018;
Van Opdenbosch et al, 2014). To examine whether a LeTx-
responsive Nlrp1b allele impacts cell death induction by the
pan-DPP inhibitor VBP (Fig S1A), we monitored the induction of
pyroptotic cell lysis over time in B6 and B6Nlrp1b+ BMDMs in function
of the number of nuclei stained with the membrane-impermeant
DNA-intercalating dye Sytox Green (SG). Consistent with published
reports (Okondo et al, 2017, 2018), by 6 h, VBP had induced low levels
of pyroptosis (~20%) in B6 BMDMs, which gradually increased to
reach a plateau at approximately 50% cytotoxicity by 24 h (Fig 1A). All
tested VBP concentrations (10, 25, and 40 μM) induced cell death
with similar kinetics and maximal cytotoxicity levels (Fig 1A), which
was consistent with the observation that exogenous DPP9 activity
was fully inhibited in lysates of BMDMs that had been pre-treated
with 10 μM VBP (Fig S2A and B and Table S1). Notably, cell death
induction was substantially faster in B6Nlrp1b+ BMDMs at all tested
concentrations with a 30% half-maximal level of pyroptosis reached
within 3 h in B6Nlrp1b+ BMDMs, whereas this same level of cytotoxicity
required about 8 h in B6 macrophages (Fig 1A). Titration studies
further showed that 1μMVBPwas sufficient to induce robust pyroptosis
in B6Nlrp1b+ BMDMs, whereas 0.1 μM of the inhibitor failed to trigger a
cytotoxic response (Fig S2C).
Acetylation of VBP (aVBP, Fig S1B) prevents inhibition of DPP
family members (Connolly et al, 2008). In agreement with inhibition
of DPP protease activity being responsible for VBP’s cytotoxic effect,
aVBP failed to induce cytotoxicity in both B6 and B6Nlrp1b+ BMDMs
(Fig 1B). We next evaluated a cyclic VBP analog (cVBP, Fig S1) that
was more than 100-fold attenuated in its ability to inhibit DPP9
activity in vitro (IC50 cVBP = 1.70 ± 0.08 μM versus IC50 VBP = 15.3 ± 0.8
nM) (Fig S2D and E and Table S1). All examined cVBP concentrations
(10, 25, and 40 μM) failed to induce cell death in B6 BMDMs (Fig 1C).
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Contrastingly, however, cVBP induced significant pyroptosis in
B6Nlrp1b+ BMDMs (Fig 1C), although cell death induction by 10 μM
cVBP still was attenuated and markedly delayed when compared
with the cytotoxic response of VBP in B6Nlrp1b+ BMDMs (Fig 1A and C).
VBP is a nonselective inhibitor of DPP8 and DPP9 that also in-
hibits the prolyl DPPs DPP4, fibroblast activation protein (FAP), and
prolyl oligopeptidase (PREP) (Waumans et al, 2015). We evaluated
inhibitors with a more confined selectivity profile to better define
the DPP family members that may contribute to the cytotoxic effect
of VBP in macrophages. Sitagliptin, UAMC39, UAMC1110, and KYP-
2047/UAMC714 (Fig S1D–G) specifically target DPP4, DPP2, FAP, and
PREP, respectively (Jansen et al, 2014; Jarho et al, 2004; Kim et al,
2005; Senten et al, 2004). We first established that treatment of
BMDMs with 10 μM sitagliptin, UAMC39, UAMC1110, or KYP-2047/
Figure 1. Transgene expression of Nlrp1b sensitizes BMDMs to cell death upon DPP8/DPP9 inhibition.
(A–H) B6 or B6Nlrp1b+ BMDMs were left untreated or treated with 10, 25, or 40 μM of VBP (A), acetyl-VBP (B), cyclic-VBP (C), sitagliptin (D), UAMC39 (E), UAMC1110 (F),
KYP-2047/UAMC714 (G), or 1G244 (H) in media containing SG and imaged on an Incucyte platform. In all graphs, the number of positive cells was quantified relative to
a Triton X100–treated well considered 100%. Values represent mean ± SD of technical duplicates of a representative experiment from three biological repeats.
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UAMC714 sufficed to reach intracellular concentrations of the re-
spective inhibitors that maximally inhibit their protease targets in
BMDMs (Fig S3 and Table S2). However, none of the listed inhibitors
triggered a cell death response in B6 and B6Nlrp1b+ BMDMs at
concentrations of 10, 25, or 40 μM, respectively (Fig 1D–G). Overall,
these results suggest that inhibition of DPP4, DPP2, FAP, and PREP
does not reflect VBP’s ability to induce pyroptosis, which may be
selectively linked to its activity on DPP8 and DPP9. Compound 1G244
(Fig S1H) is highly selective for DPP8/DPP9 over other DPP family
members, albeit targeting these enzymes with reduced potency
compared with VBP (Wu et al, 2009). Cell lysates of BMDMs that have
been treated with 10 μM 1G244 inhibited DPP8/DPP9 activity by 98%
in our in vitro assay (Fig S4A and B and Table S3), suggesting that
this concentration suffices to reach intracellular 1G244 concen-
trations that support near-complete target engagement. Consis-
tently, B6Nlrp1b+ BMDMs rapidly underwent pyroptosis when treated
with 10 μM 1G244 with a 30% half-maximal level of pyroptosis
reached within 2 h, and a plateau of about 60% pyroptosis evident
by 6 h posttreatment (Fig 1H). Increasing the 1G244 treatment
concentrations to 25 μM or 40 μM did not alter cell death kinetics
in B6Nlrp1b+ BMDMs (Fig 1H), in agreement with our in vitro ob-
servations demonstrating near full DPP8/DPP9 inhibition with
10 μM 1G244 on macrophages (Fig S4A and B and Table S3). Ti-
tration studies further showed that 1 μM 1G244 induced a reduced
level of pyroptosis in B6Nlrp1b+ BMDMs, whereas 0.1 μM of the
inhibitor failed to trigger a cytotoxic response (Fig S4C). Consistent
with the reported findings (Waumans et al, 2016; Okondo et al,
2017), 1G244 and VBP—at concentrations of 10 μM and
25 μM—elicited a swift and robust cytotoxic response in the BALB/
c-derived monocytic cell line J774.A1 that natively expresses a
LeTx-responsive Nlrp1b allele (Fig S5). As seen with VBP (Fig 1A),
the cytotoxic response of B6 BMDMs that had been treated with
10 μM or 25 μM 1G244 was markedly slower and attenuated with
pyroptosis commencing around 10 h posttreatment and reaching
~20% of the cell population by 24 h (Fig 1H). A concentration of
40 μM 1G244 reached a more potent 40% pyroptosis level by 24 h,
although the cell death kinetics remained slow (Fig 1H). Collec-
tively, these results establish that expression of a LeTx-responsive
Nlrp1b allele drives a fast and prominent pyroptosis response
upon DPP8/DPP9 inhibition in primary macrophages and in the
BALB/c-derived monocytic cell line J774.A1.
DPP8/DPP9 inhibition elicits caspase-1 cleavage and secretion of
mature IL-1β and IL-18 frommacrophages with a LeTx-responsive
Nlrp1b inflammasome
LeTx induces pyroptosis in LPS-primed B6Nlrp1b+ BMDMs concomi-
tant with the induction of Nlrp1b-dependent caspase-1 auto-
cleavage and maturation and secretion of the inflammatory
cytokines IL-1β and IL-18 (Boyden & Dietrich, 2006; Van Opdenbosch
et al, 2014, 2017). VBP and 1G244 were recently shown to induce
pyroptosis in B6 macrophages without eliciting caspase-1 auto-
maturation, or maturation and secretion of IL-1β in these cells
(Okondo et al, 2017, 2018). We sought to examine how these different
inflammasome parameters were impacted in VBP-, cVBP-, and
1G244-treated B6Nlrp1b+ BMDMs. Macrophages were primed with LPS
for 3 h before treatment with VBP, cVBP, 1G244, or aVBP at different
concentrations (0, 10 and 40 μM) and different incubation times (4,
8, and 24 h). As expected (Boyden & Dietrich, 2006; Van Opdenbosch
et al, 2014, 2017), LPS priming does not activate caspase-1 and
B6Nlrp1b+ BMDMs that had been primed with LPS for up to 24 h failed
to induce caspase-1 maturation into its prototypic p20 subunit (Fig
2A). However, VBP triggered marked caspase-1 cleavage with the
catalytic p20 subunit being evident in immunoblots of B6Nlrp1b+
BMDMs that had been treated with both tested VBP concentrations
(10 or 40 μM) and any of the examined timepoints (4, 8, and 24 h).
Consistent with our pyroptosis titration studies (Fig S2C), 1 μM VBP
was sufficient to trigger caspase-1 maturation, whereas 0.1 μM
VBP failed to induce caspase-1 auto-cleavage (Fig S6A). The inactive
VBP analog aVBP also failed to elicit caspase-1 maturation after 24 h
(Fig 2A), demonstrating the specificity of this response. Consistent
with the reduced DPP8/DPP9 inhibition by cVBP, caspase-1 p20
cleavage was detected only in lysates of macrophages that had
been treated with the highest concentration (40 μM) (Fig 2B).
Corroborating our other findings (Fig 1H), 1G244 efficiently pro-
moted caspase-1 auto-maturation into the catalytic p20 subunit as
evident from caspase-1 immunoblots of B6Nlrp1b+ BMDMs that had
been incubated with 1G244 for any of the examined time periods
(4, 8, and 24 h) and concentrations (10 or 40 μM) (Fig 2C). Moreover,
10 μM 1G244 was most optimal to induce caspase-1 cleavage
considering that 1 μM of the inhibitor triggered weak caspase-1
processing (Fig S6B). Together, these results establish that DPP8/
DPP9 inhibition elicits efficient caspase-1 maturation concurrent
with the induction of pyroptosis in macrophages expressing a
LeTx-responsive Nlrp1b allele.
Although LPS priming increases cytosolic expression levels of
proIL-1β, it is well-established that LPS priming is dispensable for
LeTx-induced caspase-1 activation by the Nlrp1b inflammasome
(Boyden & Dietrich, 2006; Van Opdenbosch et al, 2014, 2017). We
treated naive and LPS-primed macrophages with VBP, 1G244,
and cVBP to examine whether LPS priming impacts DPP8/DPP9
inhibition–induced caspase-1 auto-processing in macrophages
that express the LeTx-responsive Nlrp1b allele. Comparable
levels of caspase-1 cleavage were detected in immunoblots of naive
and LPS-pretreated B6Nlrp1b+ BMDMs that had subsequently been
stimulated with VBP, 1G244, or cVBP (Fig 2D), adding further support
to the notion that LPS-priming is dispensable for DPP8/DPP9
inhibition–induced caspase-1 maturation by the Nlrp1b inflam-
masome. As expected, cytosolic levels of proIL-1β were markedly
up-regulated in LPS-primed B6Nlrp1b+ BMDMs relative to proIL-1β
expression in naive macrophages, whereas DPP8/DPP9 inhibition
by VBP, 1G244, or cVBP was required to induce IL-1β maturation in
LPS-primed macrophages (Fig 2D). Encouraged by these observa-
tions, we next measured the levels of secreted IL-1β and IL-18 in
response to DPP8/DPP9 inhibition during 4, 8, or 24 h. As expected,
B6Nlrp1b+ BMDMs that were primed with LPS for 4, 8, or 24 h did not
secrete IL-1β or IL-18 in their extracellular medium (Fig 2E and F).
However, LPS-primed B6Nlrp1b+ BMDMs potently released IL-1β (Figs
2E and S7A) and IL-18 (Fig 2F) as early as 4 h post-VBP treatment.
Consistent with the reduced DPP8/DPP9 inhibition effect of cVBP
and its attenuated ability to trigger pyroptosis, this compound was
less efficient in eliciting extracellular secretion of IL-1β and IL-18
at 10 μM, although it triggered substantial extracellular release
of IL-1β and IL-18 at 40 μM (Fig 2E and F). Moreover, the selective
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DPP8/DPP9 inhibitor 1G244 potently triggered secretion of IL-1β and
IL-18 at each of the examined time points and drug concentrations,
whereas the inactive VBP analog aVBP failed to induce cytokine
secretion (Figs 2E and F and S7B). Collectively, these results
demonstrate that DPP8/DPP9 inhibition–induced activation of the
Nlrp1b inflammasome drives caspase-1 auto-processing into the
catalytic p20 subunit and maturation and extracellular release of
the inflammasome-dependent cytokines IL-1β and IL-18 concom-
itant with the induction of pyroptosis.
Role of ASC in DPP8/DPP9 inhibition–mediated Nlrp1b
inflammasome signaling
The bipartite inflammasome adaptor protein ASC oligomerizes in
response to inflammasome-activating cues to form ASC specks
(Lamkanfi & Dixit, 2012, 2014). These higher order structures
frequently appear as a large (1–2 μm sized) perinuclear puncta and
serve as scaffolds for caspase-1 and caspase-8 activation in
inflammasome-activated cells (Gurung et al, 2014; Van Opdenbosch
et al, 2014, 2017). Notably, DPP inhibitors VBP and 1G244 were shown
to induce pyroptosis in the ASC-deficient immortalized monocytic
cell line RAW 264.7 and in the ASC-deficient clones of the human
monocytic cell line THP1 (Okondo et al, 2017). However, whether
DPP8/DPP9 inhibition elicits ASC speck formation in ASC-sufficient
macrophages and monocytes is not known. To examine the
presence of ASC specks in B6Nlrp1b+ macrophages, BMDMs were
stimulated with 10 μM VBP or 1G244 for 4 or 8 h before cells were
fixed and immunolabelled for ASC. Confocal image analysis of DAPI-
counterstained cells showed marked ASC speck formation in re-
sponse to VBP and 1G244 (Fig 3A). As a control, mock-treated cells
Figure 2. Inhibition of DPP8/DPP9 activates the
Nlrp1b inflammasome.
(A–C, E, F) B6Nlrp1b+ BMDMs were initially primed with LPS
for 3 h, then treated with 10 μM or 40 μM of VBP, aVBP,
cVBP, or 1G244 and collected after 4, 8, and 24 h.
Combined cell lysate and supernatant samples were
immunoblotted for the indicated proteins (A–C), and
supernatants were analyzed for IL-1β (E) and IL-18 (F)
secretion. (D) Combined cell lysate and supernatant
samples of B6Nlrp1b+ BMDMs either primed or not with
LPS for 3 h and treated with 10 μM of VBP or 10 μM of
1G244 or 40 μM of cVBP were collected after 8 h and
immunoblotted for the indicated proteins. Cytokine
values represent mean ± SD of technical duplicates from
three biological repeats. All data are representative
from three biological repeats.
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failed to display ASC specks (Fig 3A). Automated quantification of
ASC specks in randomly chosen confocal micrographs confirmed
the increase in ASC speck counts following DPP8/DPP9 inhibition
(Fig 3B).
Having established that DPP8/DPP9 inhibition–induced
inflammasome activation is accompanied by the formation of ASC
specks, we bred ASC-deficient mice to B6Nlrp1b+ animals to study the
functional role of ASC in VBP- and 1G244-induced pyroptosis,
caspase-1 auto-maturation, and IL-1β secretion in Nlrp1b-sufficient
macrophages. We (Van Opdenbosch et al, 2014) and others (Guey
et al, 2014) previously reported that LeTx-induced pyroptosis
continued unabated in ASC−/− macrophages, whereas caspase-1
maturation was abolished and secretion of IL-1β attenuated. No-
tably, the maximal levels of pyroptosis induced by VBP and 1G244
were reduced by about 50% in B6Nlrp1b+ASC−/− BMDMs compared
with ASC-sufficient B6Nlrp1b+ macrophages although cell death ki-
netics remained largely unaffected (Fig 3C and D). As expected
(Guey et al, 2014; Van Opdenbosch et al, 2014), we observed
comparable kinetics and maximal levels of pyroptosis in LeTx-
treated B6Nlrp1b+ASC−/− BMDMs and B6Nlrp1b+ macrophages (Fig
S8). Akin to reported findings in the monocytic cell line RAW
264.7 (Okondo et al, 2017, 2018) (that is naturally deficient in ASC
expression [Pelegrin et al, 2008]), VBP- and 1G244-induced caspase-
1 maturation was blunted in B6Nlrp1b+ASC−/− BMDMs (Fig 3E and F).
Moreover, DPP8/DPP9 inhibition–induced secretion of IL-1β in
culture supernatants of B6Nlrp1b+ASC−/− BMDMs was reduced
compared with those of B6Nlrp1b+ cells (Fig 3G). Based on these
findings, we conclude that ASC is required for DPP8/DPP9
inhibition–induced caspase-1 maturation while partially con-
tributing to induction of pyroptosis and IL-1β secretion by the
Nlrp1b inflammasome.
DPP8/DPP9 inhibition induces ASC-mediated apoptosis in
caspase-1–deficient B6Nlrp1b+ macrophages
It was recently shown that LeTx-intoxicated B6Nlrp1b+ macrophages
switch to an ASC- and caspase-8–dependent apoptotic program
when failing to activate caspase-1 (Van Opdenbosch et al, 2017). We
bred B6Nlrp1b+ mice to caspase-1/11–deficient animals to analyse
whether DPP8/DPP9 inhibition similarly triggers apoptosis in cas-
pase-1–deficient macrophages. As expected, B6Nlrp1b+ macrophages
displayed a prototypical “necrotic ballooning” phenotype that was
indicative of pyroptosis induction following DPP8/DPP9 inhibition by
VBP or 1G244 (Fig 4A). Contrastingly, DPP8/DPP9 inhibition in B6Nlrp1b+
C1−/−C11−/− macrophages induced apoptosis as evidenced by the
appearance of apoptotic bodies (Fig 4A). We further bred B6Nlrp1b+
C1−/−C11−/− mice to ASC−/− mice to investigate whether DPP8/DPP9
inhibition–induced apoptosis was mediated by ASC specks. Notably,
VBP- and 1G244-treated B6Nlrp1b+C1−/−C11−/−ASC−/− macrophages
remained alive andwere fully rescued fromapoptosis and pyroptosis
induction (Fig 4A), akin to reported results for LeTx-stimulated
B6Nlrp1b+C1−/−C11−/−ASC−/− macrophages (Van Opdenbosch et al,
2017). As expected, cell lysis–associated internalization of the cell-
impermeant DNA-intercalating agent SG occurred in pyroptotic
1G244-treated B6Nlrp1b+ macrophages specifically, but not in early
apoptotic B6Nlrp1b+C1−/−C11−/− macrophages or cell death–resistant
B6Nlrp1b+C1−/−C11−/−ASC−/− macrophages (Fig 4B). Similar results were
obtained in VBP-treated macrophages (Fig 4C). Moreover, VBP in-
duced caspase-1 maturation in B6Nlrp1b+ macrophages, whereas
marked ASC-dependent caspase-8 cleavage was observed in cell
lysates of B6Nlrp1b+C1−/−C11−/− macrophages (Fig 4D). Finally, culture
supernatants of LPS-primed B6Nlrp1b+ macrophages that were sub-
sequently treated with VBP or 1G244 contained substantial amounts
of IL-1β (Fig 4E) and IL-18 (Fig 4F), whereas supernatants of B6Nlrp1b+
C1−/−C11−/− and B6Nlrp1b+C1−/−C11−/−ASC−/− cells lacked these cytokines
(Fig 4E and F). These results demonstrate that inhibition of DPP8/
DPP9 protease activity in caspase-1–deficient macrophages induces
ASC-dependent caspase-8 activation and apoptosis without secre-
tion of inflammasome-dependent cytokines.
Apoptosis induction in GSDMD-deficient macrophages
DPP8/DPP9 inhibition was previously shown to trigger apoptosis in
GSDMD-deficient clones of the human leukemic cell line THP-1 and
the ASC-deficient murine monocytic cell line RAW264.7 (Taabazuing
et al, 2017), akin to published findings in LeTx-stimulated GSDMD−/−
macrophages (de Vasconcelos et al, 2018). We generated B6Nlrp1b+
GSDMD−/− macrophages to address whether DPP8/DPP9 inhibition
in primary macrophages that lack GSDMD expression similarly
undergo apoptosis. The appearance of apoptotic bodies and other
hallmark features of apoptosis were evident in confocal micro-
graphs of B6Nlrp1b+GSDMD−/− macrophages that were treated for 4 h
with DPP8/DPP9 inhibitors VPB and 1G244 (Fig 5A). As controls,
GSDMD-sufficient B6Nlrp1b+ macrophages showed a pyroptotic
morphology under these conditions, whereas mock-treated con-
trols of either genotype had a healthy appearance (Fig 5A). Re-
markably, unlike in apoptotic B6Nlrp1b+C1−/−C11−/− macrophages (Fig
4B), a kinetic analysis of plasma membrane rupture in apoptotic
B6Nlrp1b+GSDMD−/− macrophages showed that cell lysis was only
slightly delayed compared with pyroptotic B6Nlrp1b+ macrophages
(Fig 5B and C), indicating that late apoptotic GSDMD-deficient cells
swiftly proceeded into secondary necrosis. However, culture
supernatants of LPS-primed B6Nlrp1b+GSDMD−/− macrophages con-
tained markedly reduced levels of IL-1β and IL-18 (Fig 5D and E),
suggesting that inflammasome-induced cytokine secretion was
primarily GSDMD-driven. In conclusion, these results demonstrate
that DPP8/DPP9 inhibitors VBP and 1G244 potently induce apo-
ptosis in primary macrophages lacking GSDMD expression.
Discussion
DPP8 and DPP9 are members of the DPP S9B family that cleave
peptide substrates after a prolyl bond (Waumans et al, 2015). In
addition to DPP8 and DPP9, this family comprises the serine pro-
teases DPP4, FAP, and PREP (Waumans et al, 2015). Myeloid cells
predominantly express DPP8 and DPP9 (Matheeussen et al, 2013).
Early studies recognized the pro-inflammatory properties of VBP, a
broad-spectrum small molecule inhibitor of DPP protease activity
(Adams et al, 2004; Nemunaitis et al, 2006). More recently, VBP was
shown to be unable to induce elevation of serum G-CSF and CXCL1/
KC levels in mice lacking caspases -1 and -11 (Okondo et al, 2017),
highlighting that inflammasome activation plays a central role in
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VBP-induced immune stimulation in vivo. Consistently, VBP and the
more selective DPP8/DPP9 inhibitor 1G244 were shown to engage
the inflammasome adaptor protein CARD8 to induce pyroptosis of a
panel of acute myeloid leukemia (AML) cell lines and primary AML
samples (Johnson et al, 2018). In addition, DPP8/DPP9 protease
activity and physical binding between DPP9 and the FIIND domain
of human NLRP1 were shown to repress activation of the NLRP1
inflammasome in human monocytes and primary keratinocytes
(Zhong et al, 2018). Notably, DPP8/DPP9 inhibition in human
monocytes and primary keratinocytes induced caspase-1 auto-
cleavage, ASC speck formation, and secretion of mature IL-1β
and IL-18 (Zhong et al, 2018), whereas VBP and 1G244 were re-
ported to induce pyroptosis without eliciting ASC speck assembly,
ASC-dependent caspase-1 auto-maturation, or maturation and
secretion of IL-1β from human THP-1 cells, murine B6macrophages,
and the immortalized monocytic cell line RAW 264.7 (Okondo et al,
2017, 2018; Johnson et al, 2018). However, a comprehensive analysis of
DPP8/DPP9-repressed inflammasome activation in primary macro-
phages expressing an Nlrp1b allele that is responsive to LeTx has not
been reported to date.
Nlrp1b allele 2 of B6 macrophages has not been decisively
shown to support inflammasome assembly. Conversely, C57BL/6J
macrophages express a functional Nlrp1a allele as highlighted
by spontaneous induction of pyroptosis of hematopoietic pro-
genitor cells and cytopenia in mice expressing an N-ethyl-N-
nitrosourea–induced gain-of-function Nlrp1aQ593P mutation
(Masters et al, 2012). Consistent with the notion that transgenic
introduction of a 129S-derived Nlrp1b allele renders B6 mouse
BMDMs susceptible to LeTx-induced pyroptosis (Boyden & Dietrich,
2006; Van Opdenbosch et al, 2014, 2017; de Vasconcelos et al, 2018),
we showed here that a LeTx-responsive Nlrp1b allele markedly
accelerated pyroptosis of B6 macrophages triggered by DPP8/DPP9
inhibition when compared with wild-type B6 macrophages that
natively express a LeTx-resistant Nlrp1b allele. Consistent with the
requirement of a responsive Nlrp1b allele for efficient pyroptosis
induction by DPP8/DPP9 inhibitors, 1G244 more potently induced
cytotoxicity in the BALB/c-derivedmyeloid leukemia cell line J774.A1
than in the wild-type B6 primary macrophages (Waumans et al,
2016). We hypothesize that the slower pyroptotic response seen in
B6 macrophages may be mediated by the Nlrp1a inflammasome.
However, addressing the role of the Nlrp1a inflammasome in DPP8/
DPP9 inhibition–induced pyroptosis awaits the generation of B6
mice with a targeted Nlrp1a null allele. Regardless, we further
established that DPP8/DPP9 inhibition–induced activation of
the Nlrp1b inflammasome drives ASC speck assembly, ASC-mediated
caspase-1 auto-processing into the catalytic p20 subunit, and mat-
uration and extracellular release of the inflammasome-dependent
cytokines IL-1β and IL-18 concomitant with induction of pyroptosis.
Our observation that ASC-deficiency in primary B6Nlrp1b+ASC−/−
BMDMs blunted caspase-1 automaturation, ASC speck assembly
and maturation and secretion of inflammasome-dependent cyto-
kines IL-1β and IL-18 is consistent with the reported absence of
caspase-1 cleavage and defective IL-1β secretion from the VBP-
treated RAW 264.7 cell line, which is naturally deficient in ASC ex-
pression (Okondo et al, 2017, 2018; Johnson et al, 2018). Moreover, we
showed that ASC is critical for caspase-8 activation and apoptosis
induction in VBP- and 1G244-treated B6Nlrp1b+ macrophages with a
deficiency in caspases -1 and -11, akin to what was reported for
LeTx-stimulated B6Nlrp1b+C1−/−C11−/− macrophages (Van Opdenbosch
et al, 2017). Finally, GSDMD-deficient B6Nlrp1b+macrophages also
switched to an apoptotic program in response to DPP8/DPP9 in-
hibition, paralleling recent findings that B6Nlrp1b+GSDMD−/− macro-
phages switch to Nlrp1b-dependent apoptosis when intoxicated
with LeTx (de Vasconcelos et al, 2018). Future work should in-
vestigate why DPP8/DPP9 inhibitor–induced apoptosis prog-
resses significantly faster to a lytic phase (as marked by SG
incorporation) in B6Nlrp1b+GSDMD−/− macrophages compared
with apoptotic B6Nlrp1b+C1−/−C11−/− BMDMs.
In conclusion, the presented work established that a LeTx-
responsive Nlrp1b inflammasome markedly accelerates DPP8/
DPP9 inhibitor–induced pyroptosis in primary macrophages and
demonstrates that this is accompanied by all hallmark features of
canonical inflammasome activation, including significant ASC speck
assembly, ASC-dependent caspase-1 autocleavage, and maturation
and secretion of inflammasome-dependent cytokines in the ex-
tracellular environment. Future studies should clarify under what
conditions canonical inflammasome hallmarks accompany
pyroptosis induction by DPP8/DPP9 inhibitors in primary human
monocytes, macrophages, and keratinocytes of healthy individuals
and diseased patients (Okondo et al, 2017, 2018; Taabazuing et al,
2017; Johnson et al, 2018; Zhong et al, 2018). Addressing this and
other questions will shed additional light on NLRP1- and CARD8-
mediated inflammasome activation, and aid translational work to




B6Nlrp1b+, ASC−/−, C1−/−11−/−, and GSDMD−/− mice have been re-
ported (Kuida et al, 1995; Mariathasan et al, 2004; Boyden &
Dietrich, 2006; Kayagaki et al, 2015) and mice were interbred to
Figure 3. Inhibition of DPP8/DPP9 elicits the inflammasome partially relying on ASC.
(A, B) ASC specks were imaged from B6Nlrp1b+ BMDMs treated with 10 μM VBP or 1G244 for 4 h or 8 h. (A) Representative confocal micrographs from three different
experiments depicting DAPI (blue) and ASC (red). Arrows indicate ASC specks. (B) Quantification of the number of cells containing an ASC speck after 8 h of treatment with
inhibitors are plotted as the mean ± SD obtained in each mosaic of three different experiments. (C, D) B6Nlrp1b+ or B6Nlrp1b+ASC−/− BMDMs were mock-treated or
received 10 μM VBP (C) or 1G244 (D) in media containing SG and imaged on an IncuCyte platform. The number of positive cells was quantified relative to a Triton
X100–treated well considered 100%. Values represent mean ± SD of technical duplicates of a representative experiment from three biological repeats. (F, G) B6Nlrp1b+ or
B6Nlrp1b+ASC−/−BMDMs were treated with 10 μM of VBP (E, G) or 1G244 (F, G) for 8 h. Combined cell lysate and supernatant samples were immunoblotted for caspase-1
(E, F) and supernatants were probed for IL-1β (G) levels. Cytokine values represent mean ± SD of technical duplicates from three biological repeats. All data are
representative from three biological repeats. Scale bars, 10 μm. ***P < 0.001; ****P < 0.0001 tested by one-way Anova with Tukey’s multiple comparisons.
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Figure 4. DPP8/DPP9 inhibition elicits cell death and cytokine release dependent on caspase-1/-11.
(A) B6Nlrp1b+, B6Nlrp1b+C1/11−/−, or B6Nlrp1b+C1/11−/−ASC−/− BMDMs were mock-treated or received 10 μM of VBP or 1G244 and imaged under a confocal microscope after 4 h.
All scale bars, 10 μm. (B, C) B6Nlrp1b+, B6Nlrp1b+C1/11−/−, or B6Nlrp1b+C1/11−/−ASC−/− BMDMs were mock-treated or received 10 μM of 1G244 (B) or VBP (C) in media
containing SG and imaged on an Incucyte platform. The number of positive cells was quantified relative to a Triton X100–treated well considered 100%. Values represent
mean ± SD of technical duplicates of a representative experiment from three biological repeats. (D) B6Nlrp1b+, B6Nlrp1b+C1/11−/−, or B6Nlrp1b+C1/11−/−ASC−/− BMDMs
were treated with 10 μM of VBP for 4 h and immunoblotted for the indicated proteins. (E, F) Supernatants from B6Nlrp1b+, B6Nlrp1b+C1/11−/−, or B6Nlrp1b+C1/11−/−ASC−/− BMDMs
primed with LPS for 3 h and treated with 10 μM 1G244 or VBP for 8 h were assayed for IL-1β (E) or IL-18 (F) levels. Cytokine values represent mean ± SD of technical duplicates
from three biological repeats. All data are representative from three biological repeats.
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obtain the desired genotypes on an hemizygous B6Nlrp1b+ genetic
background. B6 mice were originally purchased from Charles
River, and bred in-house at vivaria of Ghent University. Mice were
housed in individually ventilated cages and kept under pathogen-
free conditions. All animal experiments were conducted with
permission of the Ethics Committee on Laboratory Animal Welfare
of Ghent University.
Reagents
The DPP4 inhibitor sitagliptin, the pan-DPP inhibitors (cyclic) VBP,
the DPP8/DPP9 inhibitor 1G244, the FAP inhibitor UAMC1110
(Compound 60), the PREP inhibitor KYP-2047, and the DPP2 in-
hibitor UAMC39 (Compound 7.4) were synthesized at the Labo-
ratory of Medicinal Chemistry of the University of Antwerp
according to published protocols (Coutts et al, 1996; Jarho et al,
2004; Senten et al, 2004; Jiaang et al, 2005; Kim et al, 2005; Connolly
et al, 2008; Jansen et al, 2014). Recombinant expression and
purification of B. anthracis protective antigen (PA) was performed
as described (von Moltke et al, 2012). B. anthracis lethal factor (LF)
was acquired from List Biologicals (#172C). The antibodies used in
the study were against caspase-1 (AG-20B-0042-C100; Adipogen),
caspase-8 (8592S, D5B2, and 4790; Cell Signaling), IL-1β (GTX74034;
GeneTex), and ASC (AL177; Adipogen). HRP-conjugated anti-mouse
(115-035-146) or anti–rabbit (111-035-144) antibodies were ac-
quired from Jackson Immunoresearch Laboratories. Enhanced
chemiluminescence solution, Sytox Green (S7020), anti-rabbit
DyLight 594 (SA5-10040), and ProLong Gold Antifade Reagent
with DAPI (P36935) were purchased from Thermo Fisher Scientific.
LPS-SM (tlrl-smlps) was acquired from Invivogen. Bio-Plex kits
Pro-Mouse IL-1β (171-G5002M) and Bio-Plex Pro-Mouse IL-18 (171-
G6009M) were from Bio-Rad. Human DPP4 and DPP2 were purified
from seminal plasma, as described (de Meester et al, 1996; Maes
et al, 2005). A plasmid encoding human recombinant DPP9
(Dharmacon, Accession number: DQ892325) was expressed in Sf9
insect cells using the N-terminal BaculoDirect kit from Life
Technologies. Recombinant DPP9 was purified using immobilized
Ni-chelating chromatography (GE Healthcare), followed by anion-
exchange chromatography using a 1 ml Mono Q (GE Healthcare).
Human recombinant FAP was purchased from R&D (3715-SE).
Human recombinant PREP was expressed in BL21(DE3) cells and
purified using immobilized Co-chelating chromatography (GE
Figure 5. Cell death and cytokine release upon
inhibition of DPP8/DPP9 relies on GSDMD.
(A) B6Nlrp1b+ or B6Nlrp1b+GSDMD−/− BMDMs were either
mock-treated or received 10 μM of VBP or 1G244 and
imaged under a confocal microscope after 4 h. All scale
bars, 10 μm. (B, C) B6Nlrp1b+ or B6Nlrp1b+GSDMD−/− BMDMs
were mock-treated or received 10 μM of VBP (B) or 1G244
(C) in media containing SG and imaged on an Incucyte
platform. The number of positive cells was quantified
relative to a Triton X100–treated well considered 100%.
Values represent mean ± SD of technical duplicates of
a representative experiment from three biological
repeats. (D, E) Supernatants from B6Nlrp1b+ or B6Nlrp1b+
GSDMD−/− BMDMs primed with LPS for 3 h and treated
with 10 μMVBP or 1G244 for 4 h were assayed for IL-1β (D)
or IL-18 (E) levels. Cytokine values represent mean ± SD
of technical duplicates from three biological repeats. All
data are representative from three biological repeats.
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Healthcare) followed by anion-exchange chromatography on a
1 ml Mono Q column (GE Healthcare).
Bone marrow–derived macrophage differentiation and
stimulation
Macrophages were differentiated by culturing bone marrow pro-
genitor cells in IMDM (Lonza) containing 10% (vol/vol) heat-
inactivated FBS, 30% (vol/vol) L929 cell-conditioned medium, 1%
(vol/vol) nonessential amino acids (Lonza), 100 U/ml penicillin and
100 mg/ml streptomycin at 37°C in a humidified atmosphere
containing 5% CO2 for 6 d. BMDMs were then seeded into 96- or 24-
well plates as needed, in IMDM containing 10% FBS, 1% nonessential
amino acids, and antibiotics. On the next day, cells were changed to
fresh media and either primed or not with 100 ng/ml LPS for 3 h
before treatment with vehicle or sitagliptin (water), 1G244 (DMSO),
UAMC39 (water), UAMC1110 (DMSO), VBP (0.1%TFA in DMSO), acetyl
VBP (DMSO), cyclic VBP (0.1%TFA in DMSO), or KYP-2047/UAMC714
(DMSO) at a final concentration of 10 μM unless otherwise stated in
the figure legends. Alternatively, cells were stimulated with 1 μg/ml
PA combined with 0.5 μg/ml LF (LeTx).
J774.A1 culture and stimulation
J774.A1 cells were cultured in IMDM (Lonza) containing 10% (vol/vol)
heat-inactivated FBS, 1% (vol/vol) nonessential amino acids
(Lonza), 100 U/ml penicillin, and 100 mg/ml streptomycin at 37°C in
a humidified atmosphere containing 5% CO2. Cells were scraped for
passages and, for experiments, counted and seeded into 96-well
plates in culturing medium. On the next day, cells were changed to
fresh media and stimulated with vehicle or 1 μg/ml PA combined
with 0.5 μg/ml LF (LeTx), VBP (0.1% TFA in DMSO) or 1G244 (DMSO) at
a final concentration of 10 μM or 25 μM.
Analysis of inhibitor potency
Residual enzymatic activity in cell lysate and culture medium were
measured as described previously (Matheeussen et al, 2012). Briefly,
a calibration curve was created with known concentrations of the
inhibitor diluted in the biological sample to be analyzed. The
percentage of the residual enzymatic activity was calculated by
comparing the enzymatic activity of inhibitor-treated cells with the
activity of mock-treated cells (defined as 100% activity). To this end,
2 × 106 BMDMs were either mock-treated or stimulated with 10 μM of
VBP, cVBP, sitagliptin, UAMC39, UAMC1110, KYP-2047, or 1G244 for
15 min and supernatants were collected. For cell lysates, BMDMs
were washed once with PBS and scraped on lysis buffer (1%
octylglucoside, 10 mM EDTA, 70 μg/ml aprotinin, and 50 mM Tris–
HCl, pH 8.3). After 30 min, lysates were centrifuged at 12,000 g for
10 min at 4°C, and supernatants were collected for further analysis.
Then, each enzyme (as described below) was incubated with its
corresponding inhibitor or sample for 15 min at 37°C before the
addition of preheated substrate solution. The residual enzymatic
activity in either supernatant of cell lysates from BMDMs was
calculated as the difference between a sample with exogenously
added enzyme minus the sample without enzyme, thus correcting
for background activity. In addition, the appropriate blanks were
included to correct for differences in background activity when
constructing the calibration curves. Further experimental condi-
tions are assay-dependent and are described below. Because all
the inhibitors are reversible, the total dilution factor was consid-
ered. However, when preparing the cell lysates, an unknown di-
lution factor is introduced and the concentration calculated from
the calibration curve will be inherently an estimation of the actual
intracellular inhibitor concentration. All calibration curves were








where y is the value of the residual activity compared with a non-
inhibited sample, x is the concentration of the inhibitor in the assay,
s is the slope factor, and IC50 is the half maximal inhibitory con-
centration. The equation of the resulting graph was used to esti-
mate the concentration of the inhibitor in the culture medium or in
the cell lysate.
Sitagliptin, VBP, cVBP, and 1G244
DPP activity measurements were performed in buffer containing
0.1% Tween-20, 150 mM NaCl, 0.1 mg/ml BSA, 50 mM Tris–HCl, pH 8.3.
Glycyl-prolyl-4-methoxy-β-naphthylamide (Gly-Pro-4MeβNA) was
used as the substrate at a final concentration of 0.5 mM. For
sitagliptin, the exogenous enzyme used was human DPP4; and for
VBP, cVBP, and 1G244, human DPP9 was added. After the addition of
substrate, the release of 4MeβNA was measured kinetically with
λex = 340 nm and λem = 430 nm wavelengths for 10 min at 37°C. The
experiment was performed once and each sample/inhibitor was
measured in duplicate.
UAMC39
DPP2 activity measurements were performed in buffer containing
0.1 M acetate (pH 5.5), 10 mM EDTA, and 14 μg/ml aprotinin. Lys-Ala-
paranitroanilide (Lys-Ala-pNA) was used as substrate at a final
concentration of 1 mM. After the addition of substrate, the release
of pNA was measured kinetically with 405 nmwavelength for 10 min
at 37°C. The experiment was performed twice, and each sample/
inhibitor was measured in duplicate.
UAMC1110 and KYP-2047/UAMC714
FAP and PREP were assayed in buffer containing 0.1 M Tris–HCl
(pH 8), 300 mM NaF, 1 mM EDTA, 50 mM salicylic acid, and 5 mM
DTT. N-benzyloxycarbonyl-glycyl-prolyl-7-amido-4-methylcoumarin
(Z-Gly-Pro-AMC) was used as the substrate at a final concentra-
tion of 266 μM. After the addition of substrate, the release of AMC was
measured kinetically with λex = 380 nmand λem = 465 nmwavelengths
for 10 min at 37°C. The experiment was performed once, and each
sample/inhibitor was measured in duplicate.
Cell death kinetics
Analysis of cell death was performed through incorporation of 500
nM of Sytox Green dye in a 96-well format assay. Data were acquired
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with a 20× objective using the Incucyte Zoom system (Essen Bio-
Science) in a CO2 and temperature-controlled environment. Each
condition was run in technical duplicates. The number of fluo-
rescent objects was counted with Incucyte ZOOM (Essen Bio-
Science) software and plotted considering the highest value
obtained in a well treated with Triton—X100 as 100%.
Cytokine analysis
Cell culture supernatant was collected after 4, 8, and/or 24 h of
stimulation, and culture medium was measured by magnetic
bead–based multiplex assay using Luminex technology (Bio-Rad)
according to the manufacturer’s instructions. GraphPad Prism 6.0
software was used for data analysis.
Western blotting
Cells lysed in Laemmli buffer on ice for 10 min. Supernatants were
combined with cell lysates for detection of caspase-1 and IL-1β. For
detection of caspase-8, most of the supernatant was removed.
Subsequently, protein samples were boiled at 95°C for 10 min and
separated by SDS–PAGE. Separated proteins were transferred to
PVDF membranes. Blocking, incubation with antibody and washing
of the membrane were performed in PBS supplemented with 0.05%
or 0.1% Tween-20 (vol/vol) and 3% nonfat dry milk.
ASC speck quantification and confocal imaging
BMDMs seeded on eight-well slide chambers (ibidi) were treated for
4 h or 8 h with VBP or 1G244 and fixed with 4% (wt/vol) para-
formaldehyde. Cells were stained with anti-ASC (1:200) antibody,
followed by secondary anti-rabbit DyLight 594 (1:1,000). Then, slides
were mounted on ProLong Gold Antifade reagent with DAPI for
analysis. For quantification of ASC specks, analyses were performed
on a spinning-disk system (Zeiss), using an observer Z.1 microscope
equipped with a Yokogawa disk CSU-X1. Fluorescent images were
acquired with the use of a Plan-Apochromat 40×/1.4 oil DIC III
objective and a Rolera Em-C2 Camera. Tile scanning was performed
combining 4 × 5 images for the final mosaic (total area 7.42 mm ×
5.91 mm). The maximum intensity projections of the final mosaic
were analysed on Volocity 6.3.1 (PerkinElmer) software for the
number of cells containing ASC specks. Seven mosaics were
quantified per experimental condition from each biological repeat
and the data from all repeats were combined. One-way ANOVA with
Tukey’s multiple comparisons analysis was performed in GraphPad
Prism 6.0 software.
For bright-field imaging of cell death induction, BMDMs were
seeded on eight-well slide chambers and treated for 4 h with VBP or
1G244. Imaging was performed on the same microscope as above,
and cells were kept in a chamber with a 5% CO2 atmosphere at 37°C
throughout the experiment. Representative images were extracted
and edited in Fiji (National Institutes of Health).
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201900313.
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